CYP3A4/P-glycoprotein inhibitors related colchicine toxicity mimicking septic shock

被引:0
|
作者
Ngeyvijit, Jinjuta [1 ]
Nuansuwan, Sopita [2 ]
Phoophiboon, Vorakamol [3 ,4 ]
机构
[1] Chaophraya Abhaibhubejhr Hosp, Dept Med, Div Pulm & Crit Care Med, Prachin Buri, Thailand
[2] Chaophraya Abhaibhubejhr Hosp, Dept Med, Prachin Buri, Thailand
[3] Chulalongkorn Univ, Fac Med, Dept Med, Div Crit Care Med, Bangkok, Thailand
[4] Univ Toronto, St Michaels Hosp, Div Crit Care Med, Unity Hlth Toronto, Toronto, ON, Canada
关键词
Drug interactions; Adult intensive care; Toxicology; AMERICAN-COLLEGE; INTOXICATION; MANAGEMENT; CLARITHROMYCIN; OVERDOSE; RECOMMENDATIONS; GUIDELINE; DRUGS;
D O I
10.1136/bcr-2023-257186
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Colchicine toxicity is uncommon when patients receive a therapeutic dose regularly. However, inadvertent drug interactions can result in unpredicted adverse outcomes. The toxicity of colchicine can manifest in various ways, ranging from mild and non-specific symptoms to severe form known as multiple organ dysfunction syndrome. This case highlights (1) the diagnostic challenge that arises when distinguishing between the severe manifestation of colchicine toxicity and septic shock and (2) concomitant prescription of colchicine with potent CYP3A4 and P-glycoprotein inhibitors (ie, clarithromycin) can lead to colchicine toxicity despite normal renal and hepatic clearance. Unfortunately, specific tests of colchicine toxicity were not routinely available. A high index of clinical suspicion and recognition of drug interactions with their common presentations are crucial for making diagnosis and management. Failure to recognise drug toxicity can result in poor outcomes.
引用
收藏
页数:5
相关论文
共 50 条
  • [1] Functional interaction of intestinal CYP3A4 and P-glycoprotein
    Kivistö, KT
    Niemi, M
    Fromm, MF
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2004, 18 (06) : 621 - 626
  • [2] The barrier function of CYP3A4 and P-glycoprotein in the small bowel
    Watkins, PB
    ADVANCED DRUG DELIVERY REVIEWS, 1997, 27 (2-3) : 161 - 170
  • [3] USE OF DUAL P-GLYCOPROTEIN AND MODERATE CYP3A4 INHIBITORS WITH RIVAROXABAN OR APIXABAN INCREASES BLEEDING
    Hanigan, Sarah
    Das, Jessica
    Pogue, Kristen
    Dorsch, Michael
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 551 - 551
  • [4] Absorption of quinidine is influenced by intestinal P-glycoprotein and CYP3A4 in humans
    Glaeser, H
    Drescher, S
    Mürdter, T
    Eichelbaum, M
    Fromm, MF
    DRUG METABOLISM REVIEWS, 2003, 35 : 66 - 66
  • [5] Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4
    Cummins, CL
    Jacobsen, W
    Benet, LZ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 300 (03): : 1036 - 1045
  • [6] Potent in vitro Inhibition of CYP3A4 and P-Glycoprotein by Rhodiola rosea
    Hellum, Bent H.
    Tosse, Anita
    Hoybakk, Kathrine
    Thomsen, Mette
    Rohloff, Jens
    Nilsen, Odd Georg
    PLANTA MEDICA, 2010, 76 (04) : 331 - 338
  • [7] Impact of saturation of CYP3A4 and P-glycoprotein in vivo on the prediction of intestinal availability
    Gertz, Michael
    Harrison, Anthony
    Davis, John
    Houston, J. Brian
    Galetin, Aleksandra
    DRUG METABOLISM REVIEWS, 2009, 41 : 29 - 30
  • [8] Plasma concentrations of quinidine are determined by intestinal P-glycoprotein and CYP3A4 in humans
    Drescher, S
    Glaeser, H
    Mürdter, T
    Eichelbaum, M
    Fromm, MF
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2003, 367 : R114 - R114
  • [9] Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein
    Egashira, K
    Ohtani, H
    Itoh, S
    Koyabu, N
    Tsujimoto, M
    Murakami, H
    Sawada, Y
    DRUG METABOLISM AND DISPOSITION, 2004, 32 (08) : 828 - 833
  • [10] The drug-drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4
    Wang, Xianming
    Zhang, Xiang
    Huang, Xinhui
    Li, Yuntong
    Wu, Mengchao
    Liu, Jingfeng
    XENOBIOTICA, 2016, 46 (07) : 651 - 658